734 related articles for article (PubMed ID: 35676798)
1. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798
[TBL] [Abstract][Full Text] [Related]
2. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease.
Rhee JJ; Han J; Montez-Rath ME; Kim SH; Cullen MR; Stafford RS; Winkelmayer WC; Chertow GM
Diabetes Obes Metab; 2022 May; 24(5):928-937. PubMed ID: 35118793
[TBL] [Abstract][Full Text] [Related]
4. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
Wilkinson S; Williamson E; Pokrajac A; Fogarty D; Stirnadel-Farrant H; Smeeth L; Douglas IJ; Tomlinson LA
Diabetes Obes Metab; 2020 May; 22(5):847-856. PubMed ID: 31957254
[TBL] [Abstract][Full Text] [Related]
6. Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: A comparative cohort study from the United Kingdom.
Alkabbani W; Shah BR; Zongo A; Eurich DT; Alsabbagh MW; Gamble JM
Diabetes Obes Metab; 2023 Dec; 25(12):3490-3500. PubMed ID: 37563767
[TBL] [Abstract][Full Text] [Related]
7. The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus.
van Hulten V; Driessen JHM; Starup-Linde JK; Al-Mashhadi ZK; Viggers R; Klungel OH; Souverein PC; Vestergaard P; Stehouwer CDA; van den Bergh JP
Diabetes Obes Metab; 2023 Nov; 25(11):3235-3247. PubMed ID: 37503747
[TBL] [Abstract][Full Text] [Related]
8. Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study.
Ng PY; Ng AK; Ip A; Wu MZ; Guo R; Yiu KH
Crit Care Med; 2023 Aug; 51(8):1074-1085. PubMed ID: 37026864
[TBL] [Abstract][Full Text] [Related]
9. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
Cahn A; Melzer-Cohen C; Pollack R; Chodick G; Shalev V
Diabetes Obes Metab; 2019 Feb; 21(2):340-348. PubMed ID: 30207040
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.
Zhuo M; Paik JM; Wexler DJ; Bonventre JV; Kim SC; Patorno E
Am J Kidney Dis; 2022 Jun; 79(6):858-867.e1. PubMed ID: 34762974
[TBL] [Abstract][Full Text] [Related]
11. Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.
Cowan A; Jeyakumar N; Kang Y; Dixon SN; Garg AX; Naylor K; Weir MA; Clemens KK
Clin J Am Soc Nephrol; 2022 Jun; 17(6):835-842. PubMed ID: 35618342
[TBL] [Abstract][Full Text] [Related]
12. Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Bae JH; Park EG; Kim S; Kim SG; Hahn S; Kim NH
Endocrinol Metab (Seoul); 2021 Apr; 36(2):388-400. PubMed ID: 33789035
[TBL] [Abstract][Full Text] [Related]
13. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D
Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
[TBL] [Abstract][Full Text] [Related]
14. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
Shao SC; Chang KC; Lin SJ; Chien RN; Hung MJ; Chan YY; Kao Yang YH; Lai EC
Cardiovasc Diabetol; 2020 Feb; 19(1):17. PubMed ID: 32050968
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
Han SJ; Ha KH; Lee N; Kim DJ
Diabetes Obes Metab; 2021 Mar; 23(3):682-691. PubMed ID: 33236515
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: A systematic review and meta-analysis of observational studies.
Forbes AK; Suckling RJ; Hinton W; Feher MD; Banerjee D; Cole NI; de Lusignan S; Swift PA
Diabetes Obes Metab; 2023 Aug; 25(8):2310-2330. PubMed ID: 37202870
[TBL] [Abstract][Full Text] [Related]
17. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
[TBL] [Abstract][Full Text] [Related]
18. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
Komuro I; Kadowaki T; Bodegård J; Thuresson M; Okami S; Yajima T
Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():19-27. PubMed ID: 33835641
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus.
Fralick M; Colacci M; Thiruchelvam D; Gomes T; Redelmeier DA
Diabetes Obes Metab; 2021 Apr; 23(4):950-960. PubMed ID: 33336894
[TBL] [Abstract][Full Text] [Related]
20. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.
Zhuo M; D'Andrea E; Paik JM; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Patorno E
JAMA Netw Open; 2022 Oct; 5(10):e2235995. PubMed ID: 36219443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]